(Q44297905)

1 December 2017

title

Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response (English)

1 reference

1 December 2017

1 reference

4

Harry L Keyserling

1 reference

1 December 2017

Myong-Jin Kim

1

1 reference

1 December 2017

Anne N Nafziger

2

1 reference

1 December 2017

Clayton D Harro

3

1 reference

1 December 2017

Keith M Ramsey

5

1 reference

1 December 2017

George L Drusano

6

1 reference

1 December 2017

Joseph S Bertino

7

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

1 December 2017

1 reference

1 December 2017

volume

21

1 reference

1 December 2017

issue

11-12

1 reference

1 December 2017

page(s)

1174-1179

1 reference

Hepatitis B vaccine responsiveness in Connecticut public safety personnel

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

Persistence of anti-HBs antibodies in health care personnel vaccinated with plasma-derived hepatitis B vaccine and response to recombinant DNA HB booster vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

Intradermal hepatitis B vaccination in health care workers. Response rate and experiences from vaccination in clinical practise

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

Duration of immunity after hepatitis B vaccination: efficacy of low-dose booster vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

Prediction of response to hepatitis B vaccine in health care workers: whose titers of antibody to hepatitis B surface antigen should be determined after a three-dose series, and what are the implications in terms of cost-effectiveness?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

Immunogenicity of a recombinant hepatitis B vaccine in adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre-S2 particles for revaccination of healthy adult nonresponders

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

Randomized, comparative trial of 20 micrograms vs 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

Reversal of nonresponders and postexposure prophylaxis by intradermal hepatitis B vaccination in Japanese medical personnel

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

Vaccine adjuvancy: a new potential area of development for GM-CSF.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

Seroconversion after additional vaccine doses to non-responders to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

Adjuvants--a balance between toxicity and adjuvanticity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

The dendritic cell system and its role in immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

Prediction of the role of granulocyte-macrophage colony-stimulating factor in animals and man from in vitro results

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

Evaluation of tolerability and antibody response after recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

Granulocyte-macrophage colony-stimulating factor given as an adjuvant to persons not responding to hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

Granulocyte-macrophage colony-stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

Granulocyte-macrophage colony-stimulating factor as an adjuvant to hepatitis B vaccination in maintenance hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

The effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hepatitis B vaccination in haemodialysis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900626-6

7 January 2021

10.1016/S0264-410X(02)00626-6

Identifiers

DOI

1 reference

1 December 2017

1 reference